Key cancer patents killed

A federal judge ruled yesterday (March 29) to invalidate seven patents related to two genes associated with breast cancer, casting doubt on the thousands of other patents covering human genes. Image: Wikimedia commons"If a decision like this were upheld, it would have a pretty significant impact on the future of medicine," Kenneth Chahine, a visiting law professor at the University of Utah, linkurl:told the New York Times.;http://www.nytimes.com/2010/03/30/business/30gene.html Chahine filed an

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A federal judge ruled yesterday (March 29) to invalidate seven patents related to two genes associated with breast cancer, casting doubt on the thousands of other patents covering human genes.
Image: Wikimedia commons
"If a decision like this were upheld, it would have a pretty significant impact on the future of medicine," Kenneth Chahine, a visiting law professor at the University of Utah, linkurl:told the New York Times.;http://www.nytimes.com/2010/03/30/business/30gene.html Chahine filed an amicus brief on the side of Myriad Genetics, which held the patents for the genes in question, BRCA1 and BRCA2. About 20 percent of human genes have been patented, and currently support billions of dollars worth of industry. linkurl:A study published earlier this month;http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WG1-4YK2F2W-1&_user=10&_coverDate=03%2F10%2F2010&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=37b70c97b21342dc6d1086d01d75a2af in Genomics argued that one of the patents should linkurl:never have been granted;http://www.the-scientist.com/community/posts/list/925.page in the first place. The 1998 patent for BRCA1 is too broad, according to the study -- containing more than 300,000 oligonucleotides, many of which were part of 80 percent of the cDNA and mRNA sequences in GenBank before the patent application was even filed. Genes, as products of nature, should not be patentable, and the patents for the BRCA1 and BRCA2 genes were stifling breast cancer research, argued the American Civil Liberties Union, the Public Patent Foundation at the Benjamin N. Cardozo School of Law in New York, and others challenging the patents. Patent holders Myriad Genetics and the University of Utah Research Foundation, however, claimed that the process of isolating the DNA transforms it in a way that makes it patentable. Judge Robert W. Sweet sided with the plaintiffs, saying that the patents were "improperly granted" because they involved a "law of nature." If this decisions stands, Chahine said, "the industry is going to have to get more creative about how to retain exclusivity and attract capital in the face of potentially weaker patent protection."
**__Related stories:__***linkurl:Gene patents -- too broad?;http://www.the-scientist.com/community/posts/list/925.page
[17th March 2010]*linkurl:Patents for cancer genes?;http://www.the-scientist.com/community/posts/list/857.page
[10th February 2010]*linkurl:Concern over BRCA2 patent;http://www.the-scientist.com/article/display/22678/
[16th May 2005]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform